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BACKGROUND: Increased systolic blood pressure variability (BPV) is associated with stroke, cardiovascular disease, and dementia and mild cognitive impairment. However, prior studies assessing the relationship between BPV and dementia or mild
cognitive impairment had infrequent measurement of blood pressure or suboptimal blood pressure control.
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METHODS AND RESULTS: We performed a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial) MIND
(Memory and Cognition in Decreased Hypertension) trial. The primary outcome was probable dementia during follow-up.
We defined our exposure period, during which blood pressures were collected, as the first 600 days of the trial, and outcomes were ascertained during the subsequent follow-up. BPV was measured as tertiles of systolic blood pressure standard
deviation. We fit Cox proportional hazards models to our outcome. We included 8379 patients. The mean follow-up was
3.2±1.4 years, during which 316 (3.8%) patients developed dementia. The mean number of blood pressure measurements
was 7.8, and in the tertiles of BPV, the SD was 6.3±1.6, 10.3±1.1, and 16.3±3.6 mm Hg, respectively. The rate of dementia was
2.4%, 3.6%, and 5.4% by ascending tertile, respectively (P<0.001). In the Cox models, compared with the lowest tertile of BPV,
the highest tertile of BPV increased the risk of dementia in both unadjusted (hazard ratio [HR], 2.36; 95% CI, 1.77–3.15) and
adjusted (HR, 1.69; 95% CI, 1.25–2.28) models.
CONCLUSIONS: In a post hoc analysis of the SPRINT MIND trial, we found that higher BPV was associated with the development
of probable dementia despite excellent blood pressure control. Additional research is needed to understand how to reduce
BPV and if its reduction lowers the risk of cognitive impairment and dementia.
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I

ncreased systolic blood pressure variability (BPV)
has been linked to the development of stroke, cardiovascular disease, and dementia and mild cognitive impairment (MCI), independent of mean blood
pressure.1,2 In addition, research has demonstrated the
importance of blood pressure control for the prevention of dementia and MCI.3 However, previous studies
evaluating the relationship between BPV and dementia
or MCI relied on longitudinal cohorts, with infrequent
measurement of blood pressure or suboptimal blood

pressure control.2 We hypothesized that in a cohort
with frequent visit-
to-
visit blood measurements and
excellent blood pressure control, BPV would retain its
harmful effects on cognition.

METHODS
We performed a post hoc analysis of the SPRINT
(Systolic Blood Pressure Intervention Trial) MIND
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(Memory and Cognition in Decreased Hypertension)
trial, using a publicly available deidentified data set
supplied by the National Heart, Lung, and Blood
Institute.4 Institutional review board approval or participant consent was not required for this post hoc
analysis of deidentified data per University of Utah institutional review board policy. Our primary outcome
was incident probable dementia, and secondary outcomes were MCI and the composite of dementia/
MCI. The rigorous adjudication of probable dementia
and MCI in the SPRINT MIND trial has previously been
described and relied on both screening and adjudication at follow-up visits and planned cognitive testing at
years 2 and 4, and study closeout when it was >1 year
after the year-4 evaluation.4 We defined our exposure
period, during which blood pressures were collected
at study visits, as the first 600 days of the SPRINT trial,
and outcomes were recorded during the subsequent
SPRINT MIND follow-up period.
The exposure of visit-to-visit BPV was measured as
tertiles of systolic blood pressure SD, and to improve
accuracy of BPV measurement, we excluded patients
with <4 blood pressure measurements. In the SPRINT
trial, trained study personnel recorded seated blood
pressures according to a protocol at scheduled study
visits. The blood pressure used in the present study is
a single value per visit that represents the average of 3
seated blood pressures at each study visit. To standardize the time between blood pressure measurements,
we excluded as-needed study visit blood pressures,
and to limit the confounding of trial interventions, we
also excluded the baseline visit blood pressure. We included blood pressures from up to 9 scheduled visits
at 1, 2, 3, 6, 9, 12, 15, 18, and 21 months from enrollment. We calculated the SD using the formula:

√(
SD =

1
n−1

)
∑ (n)
(i = 1)

(BPi − BPmean )2 .

We fit Cox proportional hazards models to our outcomes and a priori adjusted for patient age, sex, race/
ethnicity, history of cardiovascular disease, hypertension, education, level of physical activity, current smoking status, SPRINT randomization arm, number of blood
pressure measurements, and mean systolic blood pressure during the exposure. We verified the proportional
hazards assumption of our final model (global test,
P=0.498). We also included the interaction of randomization arm×BPV in our model and then stratified by randomization arm to explore the effect of BPV in patients
with standard versus intensive blood pressure control.
We subsequently tested the interactions between BPV
and the other covariates in our adjusted model. As a
sensitivity analysis, we confirmed our results using coefficient of variation and residual SD to generate tertiles

of BPV, instead of SD. All analyses were performed in
Stata 16.1 (StataCorp, College Station, TX).

RESULTS
Of the 8563 patients who completed at least 1 cognitive assessment in the SPRINT MIND trial, we included 8379 and excluded 110 for insufficient blood
pressure data, 24 for having the outcome or being
right-censored during the exposure period, and 32 for
having missing demographic data or covariates in our
adjusted model. Baseline demographics are shown
in Table 1. During the 600-day exposure period, the
mean number of systolic blood pressure measurements was 7.8±0.6, and mean systolic blood pressure
was 128.5 mm Hg. In the tertiles of BPV, the SD was
6.3±1.6, 10.3±1.1, and 16.3±3.6 mm Hg, respectively.
The mean follow-up was 3.2±1.4 years, during which
316 (3.8%) patients developed dementia. In tertiles of
increasing BPV, the rate of dementia was 2.4%, 3.6%,
and 5.4%, respectively (P<0.001). Similar increases
were seen for the secondary outcomes (Table 1).
In the Cox models, the highest tertile of BPV, compared with the lowest, increased the risk of dementia
in both unadjusted (hazard ratio [HR], 2.36; 95% CI,
1.77–3.15) and adjusted (adjusted HR, 1.69; 95% CI,
1.25–2.28) models (Table 2). For the secondary outcomes, we found that the highest tertile of BPV was
associated with both MCI (adjusted HR, 1.40; 95% CI,
1.14–1.71), and the composite of dementia/MCI (adjusted HR, 1.43; 95% CI, 1.20–1.71) (Table 2). The interaction term between randomization arm and BPV
was not significant (P=0.557), indicating that the effect
of BPV was present in both the standard and intensive
blood pressure control arms. The Kaplan-Meier curves
for the tertiles of BPV after stratification by randomization arm are shown in the Figure and demonstrate
a consistent relationship between higher BPV and the
risk of dementia in both randomization arms.
We tested the interactions between BPV and the
other covariates in our adjusted model and found that
none had a significant interaction (all P>0.1). In the
sensitivity analysis, where we used coefficient of variation and residual standard deviation to make tertiles
of BPV, we found consistent results. For example, in
the adjusted model fit to our primary outcome, the HR
for dementia in the top tertile of coefficient of variation
was 1.53 (95% CI, 1.15–2.05), whereas in the top tertile of residual standard deviation it was 1.81 (95% CI,
1.33–2.46).

DISCUSSION
In a post hoc analysis of the SPRINT MIND trial, we
found that visit-to-visit BPV was associated with the
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Table 1. Baseline Demographics in the Full Cohort and Tertiles of BPV
Variable

Full cohort,
n=8379

Lowest tertile of
BPV, n=2796

Middle tertile of
BPV, n=2791

Highest tertile
of BPV, n=2792

P value*

Age, y

67.9±9.3

66.7±8.9

67.8±9.1

69.1±9.5

<0.001

Age ≥75 y

2049 (24.5%)

564 (20.2%)

644 (23.1%)

841 (30.1%)

<0.001

Male sex

5438 (64.9%)

1968 (71.0%)

1849 (66.3%)

1603 (57.4%)

<0.001

White

4913 (58.6%)

1589 (56.8%)

1730 (62.0%)

1594 (57.1%)

<0.001

Black

2458 (29.3%)

807 (28.9%)

753 (27.0%)

898 (32.2%)

Hispanic

866 (10.4%)

349 (12.5%)

265 (9.5%)

252 (9.0%)

Other†

142 (1.7%)

51 (1.8%)

43 (1.5%)

48 (1.7%)

History of diabetes

137 (1.6%)

34 (1.2%)

49 (1.8%)

54 (1.9%)

0.088

History of hypertension

7779 (92.8%)

2553 (91.3%)

2588 (92.7%)

2638 (94.5%)

<0.001

History of peripheral vascular disease, n=8371

448 (5.4%)

121 (4.3%)

137 (4.9%)

190 (6.8%)

<0.001

History of atrial fibrillation, n=8366

657 (7.9%)

198 (7.1%)

208 (7.5%)

251 (9.0%)

0.017

History of cardiovascular disease

1663 (19.9%)

494 (17.7%)

518 (18.6%)

651 (23.3%)

<0.001

History of stroke, n=8377

44 (0.5%)

14 (0.5%)

11 (0.4%)

19 (0.7%)

0.325

Never

3713 (44.3%)

1276 (45.6%)

1237 (44.3%)

1200 (43.0%)

<0.001

Past

3601 (43.0%)

1219 (43.6%)

1201 (43.0%)

1181 (42.3%)

Current

1065 (12.7%)

301 (10.8%)

353 (12.7%)

411 (14.7%)

324 (3.9%)

95 (3.4%)

112 (4.0%)

117 (4.2%)

0.270

≤1/wk

4486 (53.6%)

1406 (50.3%)

1486 (53.2%)

1594 (57.1%)

<0.001

1–4/wk

2767 (33.0%)

993 (35.5%)

902 (32.3%)

872 (31.2%)

≥5/wk

1126 (13.4%)

397 (14.2%)

403 (14.5%)

326 (11.7%)

Aspirin use

4313 (51.5%)

1422 (50.9%)

1428 (51.2%)

1463 (52.4%)

0.481

Retired

5036 (60.1%)

1558 (55.7%)

1689 (60.5%)

1789 (64.1%)

<0.001

Less than college/other

5053 (60.3%)

1611 (57.6%)

1655 (59.3%)

1787 (64.0%)

<0.001

College

1227 (14.6%)

437 (15.6%)

412 (14.8%)

378 (13.5%)

Grad school

2099 (25.1%)

748 (26.8%)

724 (25.9%)

627 (22.5%)

Randomized to intensive blood pressure arm

4214 (50%)

1498 (53.3%)

1412 (50.3%)

1304 (46.4%)

<0.001

Mean no. of antihypertensive medications during follow-up

2.7±1.2

2.5±1.1

2.7±1.2

3.0±1.2

<0.001

No. of blood pressure measurements

7.8±0.7

7.8±0.7

7.8±0.7

7.7±0.7

0.002

Mean systolic blood pressure during the exposure

128.5±9.8

126.2±9.7

128.1±9.3

131.2±9.8

<0.001

Percentage of study visits with hypotension, SBP <90 or
DBP <50 mm Hg

2.1±8.5

1.2±6.9

1.7±7.7

3.4±10.3

<0.001

Systolic blood pressure at the beginning of the exposure

128.4±14.6

126.1±11.4

127.9±13.1

131.1±18.1

<0.001

Systolic blood pressure at the end of the exposure

127.6±14.9

125.9±11.6

127.2±13.4

129.6±18.5

<0.001

Standard deviation of systolic blood pressure

10.9±4.7

6.3±1.6

10.3±1.1

16.3±3.6

<0.001

Race/ethnicity

Smoking

Alcoholism
Vigorous physical activity
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Education

*P value is for the comparison between the tertiles of BPV, tested with the χ2 test for binary variables and ANOVA for interval variables. Binary variables are
presented as n (%) and interval variables as mean±SD. BPV indicates blood pressure variability; DBP, diastolic blood pressure; and SBP, systolic blood pressure.
†
SPRINT.

development of probable dementia, MCI, and the
composite of both. This association was present in
both the standard and intensive target blood pressure randomization arms, indicating residual risk in
the intensive arm, some of which may be attributable
to BPV. The implication of these findings is that BPV
has an impact on cognition independent of mean
blood pressure. Prior longitudinal studies have found

similar findings, but either relied on blood pressure
readings at study visits separated by years,5–8 daily
readings for less than a month,9 or dementia adjudication that was not as robust.10 In addition, the existing data are largely from community-dwelling cohorts
with higher mean blood pressure than the SPRINT
MIND cohort.2 We show that despite the excellent
blood pressure control in the SPRINT MIND trial, BPV
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Table 2. Event Rate of the Outcomes by Tertiles of Systolic Standard Deviation and Cox Proportional Hazards Models Fit
to the Outcomes
Outcome

Tertile of systolic standard
deviation (range in mm Hg)

Event rate, n, %

Unadjusted hazard
ratio (95% CI)

Probable dementia

Lowest (0.5– 8.5)

67/2796, 2.4%

Ref

…

Ref

…

Middle (8.5–12.3)

99/2791, 3.6%

1.51 (1.11–2.06)

0.009

1.39 (1.02–1.91)

0.037

Highest (12.3– 41.1)

150/2792, 5.4%

2.36 (1.77–3.15)

<0.001

1.69 (1.25–2.28)

0.001

Lowest (0.5– 8.5)

169/2796, 6.0%

Ref

…

Ref

…

Middle (8.5–12.3)

195/2791, 7.0%

1.18 (0.96–1.45)

0.119

1.13 (0.92–1.40)

0.237

Highest (12.3– 41.1)

264/2792, 9.5%

1.64 (1.36–2.00)

<0.001

1.40 (1.14–1.71)

0.002

Lowest (0.5– 8.5)

218/2796, 7.8%

Ref

…

Ref

…

Middle (8.5–12.3)

264/2791, 9.5%

1.24 (1.04–1.48)

0.020

1.17 (0.97–1.40)

0.094

Highest (12.3– 41.1)

370/2792, 13.3%

1.94 (1.51–2.11)

<0.001

1.43 (1.20–1.71)

<0.001

Mild cognitive
Impairment

Composite of probable
dementia and mild
cognitive impairment

P value

Adjusted hazard
ratio* (95% CI)

P value

*Adjusted for patient age, sex, race/ethnicity, history of cerebrovascular disease, hypertension, education, level of physical activity, smoking status,
percentage of study visits during the exposure with hypotension (SBP <90 or DBP <50 mm Hg), mean SBP during the exposure, and randomization arm. DBP
indicates diastolic blood pressure; Ref, reference; and SBP, systolic blood pressure.

remains a risk factor for developing cognitive impairment, which is a key outcome for older adults and
warrants additional preventative research and routine
screening in primary care.11
There are several potential explanations for the association between increased BPV and dementia or

MCI. Although increased BPV has been associated
with a higher risk of stroke,12 which is associated with
dementia, we did not find a difference in the rate of
stroke in the tertiles of BPV. Secondary to the stiffer
arteries that can cause increased BPV, BPV has been
linked to intermittent cerebral hypoperfusion, which
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Figure. Kaplan-Meier curves showing failure rates for probable dementia in the first 1500 days of
follow-up after stratification by the standard vs intensive blood pressure reduction arm in SPRINT.
BP indicates blood pressure; HR, hazard ratio; MCI, mild cognitive impairment; and SPRINT, Systolic
Blood Pressure Intervention Trial.
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can predispose to vascular dementia.2 A study also
showed an association between increased BPV and
neurofibrillary tangle pathology on autopsy, which is
the hallmark of Alzheimer disease, as opposed to vascular dementia.8 Hypotension has been identified as a
potential risk factor for the development of dementia.13
Although we found that hypotension at study visits was
more common in patients in higher tertiles of BPV, we
adjusted for hypotension in our multivariate models,
and the association between increased BPV and dementia remained significant.
Ultimately, the exact mechanism by which increased BPV may cause dementia remains uncertain, and increased BPV may be an epiphenomenon
of another unidentified causal mechanism. Although
post hoc analyses can identify a potential risk factor,
there is always unmeasured confounding. A randomized clinical trial that attempts to lower the variability
and mean of blood pressure, and with the end point
of dementia or MCI, will be necessary to determine
if BPV is a viable treatment target. Because both
short-term and longer-term visit-to-visit increased
BPV have both been associated with dementia and
cardiovascular events,9,14 to identify patients with
increased BPV for such a trial, the inclusion criteria
could have a qualifying period with 12 or 24 hours
of ambulatory blood pressure monitoring. Prior research has shown that calcium channel blockers can
reduce BPV, but the goal of reducing both systolic
blood pressure mean and variability will require sophisticated medication titration.15 Before a clinical
trial can address the question of the therapeutic effects of lowering BPV, additional research is needed
to determine how BPV will be reduced and if that
reduction is safe.
Our study has several limitations, including that it
is a post hoc analysis of a trial that was not designed
to answer the proposed hypothesis. There are not
identical exposures between patients, because the
frequency of blood pressure measurement was dependent on the randomization arm, which may have
introduced bias, although the mean number of measurements in the standard versus intensive arm did
not differ significantly (7.8 versus 7.8 measurements,
respectively; P=0.53), and the difference in the tertiles of BPV was not meaningfully different. We also
were not able to examine neuroimaging mediators of
the observed association, such as chronic microvascular disease or brain atrophy, because repeat brain
magnetic resonance imaging was only available in a
subset of patients, and the final study magnetic resonance imaging was at 48 months. The strengths
of our study are that the outcome of dementia was
rigorously adjudicated in the SPRINT MIND trial, patients had excellent blood pressure control, and we
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had an average of 7.8 blood pressure readings available for determining BPV.

CONCLUSIONS
In the SPRINT MIND study, blood pressure variability
during the first 600 days was associated with subsequent development of probable dementia or MCI, despite excellent blood pressure control. The practical
implication of this finding is that additional research is
needed to understand how to reduce blood pressure
variability and if its reduction lowers the risk of cognitive impairment and dementia.
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